These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32538593)

  • 41. Direct oral anticoagulants: unique properties and practical approaches to management.
    Barnes GD; Kurtz B
    Heart; 2016 Oct; 102(20):1620-6. PubMed ID: 27402803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of direct oral anticoagulants in very elderly patients: a case report of apixaban in an ultracentenary patient.
    Manno G; Novo G; Corrado E; Coppola G; Novo S
    J Cardiovasc Med (Hagerstown); 2019 Jun; 20(6):403-405. PubMed ID: 30762659
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use.
    Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005894. PubMed ID: 32160790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome.
    Douros A; Schlemm L; Bolbrinker J; Ebinger M; Kreutz R
    Thromb Haemost; 2014 Aug; 112(2):419-20. PubMed ID: 24695752
    [No Abstract]   [Full Text] [Related]  

  • 47. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modification of In-Hospital Recommendation and Prescription of Anticoagulants for Secondary Prevention of Stroke after Launch of Direct Oral Anticoagulants and Change of National Guidelines.
    Gronemann C; Hause S; Assmann A; Neumann J; Schreiber S; Heinze HJ; Goertler M
    Cerebrovasc Dis; 2020; 49(4):412-418. PubMed ID: 32756054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics.
    Seelig J; Pisters R; Hemels ME; Huisman MV; Ten Cate H; Alings M
    Vasc Health Risk Manag; 2019; 15():399-408. PubMed ID: 31571891
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
    Hospodar AR; Smith KJ; Zhang Y; Hernandez I
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
    Miao B; Alberts MJ; Bunz TJ; Coleman CI
    J Thromb Thrombolysis; 2019 Oct; 48(3):366-372. PubMed ID: 31228038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
    Said A; Keeney S; Matka M; Hafeez A; George J; Halalau A
    BMC Cardiovasc Disord; 2020 Jun; 20(1):263. PubMed ID: 32487114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.